Table 2.

Efficacy of CVnCoV against virologically confirmed COVID-19 occurring 15 days or more after the second dose in the primary efficacy analysis set

	CVnCoV		Placebo		Vaccine efficacy (95% CI)
	n/N	Person-years	n/N	Person-years
COVID-19 of any severity
Overall	83/12 851	1735·29	145/12 211	1569·87	48·2% (31·0–61·4)*
18–60 years	71/11 532	1591·47	136/11 031	1449·23	52·5% (36·2–64·8)
≥61 years	12/1319	143·82	9/1180	120·64	..†
COVID-19 of any severity by region‡
Europe	21/4091	684·22	33/3919	604·83	43·7% (−0·2 to 69·1)
Latin America	62/8760	1051·07	112/8292	965·03	49·2% (30·1–63·3)
COVID-19 of any severity by strain§
Alpha variant (B.1.1.7/501Y.V2)	20/11 532	1591·47	42/11 031	1449·23	55·1% (23·5–73·6)
Gamma variant (P.1/501Y.V3)	9/11 532	1591·47	26/11 031	1449·23	67·1% (29·8–84·6)
Lambda variant (C.37)	13/11 532	1591·47	26/11 031	1449·23	52·8% (8·2–75·8)
Mu variant (B.1.621)	11/11 532	1591·47	17/11 031	1449·23	..†
Other	7/11 532	1591·47	13/11 031	1449·23	..†
Moderate-to-severe COVID-19
Overall	12/12 851	1735·29	37/12 211	1569·87	70·7% (42·5–86·1)
18–60 years	9/11 532	1591·47	36/11 031	1449·23	77·2% (51·8–90·4)
≥61 years	3/1319	143·82	1/1180	120·64	..†
Severe COVID-19
Overall	4/12 851	1735·29	10/12 211	1569·87	..†
18–60 years	2/11 532	1591·47	9/11 031	1449·23	..†
≥61 years	2/1319	143·82	1/1180	120·64	..†

^*For COVID-19 of any severity, the 95·826% CI is provided (due to adjustment for multiplicity across interim analyses).

^†Not reported; the number of cases was too low to be statistically meaningful.

^‡Vaccine efficacy by region was evaluated post-hoc.

^§Efficacy against strains was evaluated in adjudicated and sequenced cases in participants aged 18–60 years; other strains includes B.1 lineage SARS-CoV-2.